Primetime for antiangiogenic therapy

Area of Science:

• Neuro-oncology
• Cancer therapy
• Molecular biology

Background:

• Gliomas are aggressive brain tumors with limited treatment options.
• Angiogenesis plays a critical role in glioma growth and progression.
• Antiangiogenic therapies target tumor vasculature to inhibit growth.

Purpose of the Study:

• To review current clinical experience with angiogenesis inhibitors in glioma treatment.
• To discuss mechanisms of resistance to antiangiogenic therapy.
• To explore future therapeutic strategies for malignant gliomas.

Main Methods:

• Review of recent clinical trials involving angiogenesis inhibitors for gliomas.
• Analysis of mechanisms of resistance, including phenotypic changes and alternative pathways.
• Discussion of combination therapy approaches.

Main Results:

• Bevacizumab is approved for recurrent glioblastomas, with promising agents under investigation.
• Radiological response rates are high, but often short-lived.
• Tumor recurrence is associated with increased invasiveness and resistance.
• Observed effects may be due to blood-brain barrier normalization rather than direct antitumor activity.

Conclusions:

• Antiangiogenic therapy offers modest benefits in glioma treatment, with poor overall survival.
• Mechanisms of resistance include induction of invasive phenotypes and activation of proangiogenic pathways.
• Combination regimens targeting multiple pathways are crucial for overcoming resistance.
• Future research should focus on developing novel strategies to enhance the efficacy of antiangiogenic therapy in malignant gliomas.